

Special Issue

Molecular Targets for Breast Cancer Therapy

Message from the Guest Editor

After the cytotoxic chemotherapy era that was stained with horrific toxicities and multi-drug resistance, “molecularly targeted drugs” brought new hope to the battle against cancer. Despite the occasional introduction of new drugs, resistance seems to be inevitable. A sub-population of the tumor cells often fails to respond favorably to the initial treatment (likely due to tumor cell heterogeneity causing intrinsic resistance). This “Darwinian clone selection” is documented in different types of cancer in response to a variety of molecularly targeted drugs. On the other hand, initially responsive cells become resistant shortly after repeated doses (acquired resistance), which, in addition to point mutations, could be due to the plasticity of cancer cells that have access to a variety of signaling pathways that can compensate for the targeted protein. Therefore, the identification of new targets is crucial for overcoming these obstacles. This Special Issue focuses on breast cancer and sheds the spotlight on the most recent efforts in the identification of novel molecular targets or the newly discovered crosstalk among the established signaling pathways.

Guest Editor

Dr. Hamidreza Montazeri Aliabadi

Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Harry and Diane Rinker Health Science Campus, Irvine, CA 92618, USA

Deadline for manuscript submissions

closed (29 February 2024)



Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



mdpi.com/si/151620

Biomolecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomolecules@mdpi.com

[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)





Biomolecules

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.2
Indexed in PubMed



[mdpi.com/journal/
biomolecules](https://mdpi.com/journal/biomolecules)



About the Journal

Message from the Editorial Board

Biomolecules is a multidisciplinary open-access journal that reports on all aspects of research related to biogenic substances, from small molecules to complex polymers. We invite manuscripts of high scientific quality that pertain to the diverse aspects relevant to organic molecules, irrespective of the biological question or methodology. We aim for a competent, fair peer review and rapid publication. Please look at some of the exciting work that has been published in *Biomolecules* so far. We would be delighted to welcome you as one of our authors.

Editors-in-Chief

Prof. Dr. Peter E. Nielsen

Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3C, DK-2200 Copenhagen, Denmark

Prof. Dr. Lukasz Kurgan

Department of Computer Science, Virginia Commonwealth University, Richmond, VA 23284, USA

Author Benefits

Open Access

— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Biochemistry)